Cullinan Therapeutics unveils new Phase 2b trial data at ESMO 2025

Traders Union
All News
Market Voices
Cullinan unveils trial data

Top Stories

Editors' Picks

Crypto News

Financial News

Market Voices

Billionaires

Companies

Broker News

Regulators News

Iryna Sazhynska

18.10.2025

Cullinan Therapeutics unveils new Phase 2b trial data at ESMO 2025 — @CullinanTx: Cullinan unveils trial data

Cullinan Therapeutics is set to present new data from its Phase 2b REZILIENT2 trial during a mini oral presentation at ESMO 2025 tomorrow.

The focus will be on patients with non-small cell lung cancer (NSCLC) who have EGFR ex20ins mutations, or other EGFR uncommon non-ex20ins mutations, and active brain metastases. This presentation marks a significant step in Cancer research, providing insights into less common mutations and their treatment options. As the trial advances, the medical community and patients may gain new therapeutic insights that could influence future treatment protocols.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Kospi Index crash: Why South Korean market fell alongside AI stocks

By Eugene Komchuk
1 hour ago

Kospi Index crash: Why South Korean market fell alongside AI stocks

Editors' Picks

Bitcoin or Ferrari: Which investment is better?

By Mira Kyivska
23 hours ago

Bitcoin or Ferrari: Which investment is better?

Editors' Picks

Strategy sells Bitcoin: Small sale tests market confidence

By Mira Kyivska
Yesterday

Strategy sells Bitcoin: Small sale tests market confidence

Editors' Picks

All Editors' Top Picks

Latest Cullinan News

$Cullinan Therapeutics presents initial clinical data for CLN-978 in refractory SLE and RA$

By Anastasiia Chabaniuk
Yesterday

Cullinan Therapeutics presents initial clinical data for CLN-978 in refractory SLE and RA

Companies

Cullinan Therapeutics explores B cell depletion in novel autoimmune treatments

By Eugene Komchuk
03.06.2026

Cullinan Therapeutics explores B cell depletion in novel autoimmune treatments

Companies

Cullinan Therapeutics to unveil initial clinical data on CD19 and BCMA T cell engagers

By Dmytro Kharkov
26.05.2026

Cullinan Therapeutics to unveil initial clinical data on CD19 and BCMA T cell engagers

Companies

All Cullinan News

Eugene Komchuk
1 hour ago

Kospi Index crash: Why South Korean market fell alongside AI stocks

Mira Kyivska
23 hours ago

Bitcoin or Ferrari: Which investment is better?

Mira Kyivska
Yesterday

Strategy sells Bitcoin: Small sale tests market confidence

Mikhail Vnuchkov
05.06.2026

Ledger vs. Trezor: Search for ideal crypto wallet

Oleg Tkachenko
04.06.2026

Trading thin air: Why Binance is closing its NFT marketplace

Artem Shendetskii
18 min ago

Latam bonds quietly outperform other markets this year, Louis-Vincent Gave discusses

Andreas Kristo
23 min ago

Federal Reserve has missed 2 percent target for 63 months, Ronnie Stoeferle notes

Hanna Syniavska
1 hour ago

Joe Nakamoto: Selling lower-quality crypto assets for bitcoin brings greater focus

Jose Antonio Gastelum
1 hour ago

Stephan Livera: Building wealth with bitcoin requires long-term commitment

Igor Krasulya
1 hour ago

€4 million capital markets transaction completed rapidly, Michael Geike points out

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Igor Krasulya
49 min ago

Nvidia bets on South Korea in AI infrastructure race

Nvidia bets on South Korea in AI infrastructure race

Olga Shendetskaya
1 hour ago

Oil rises above $97 after new Israel-Iran exchange of strikes

Oil rises above $97 after new Israel-Iran exchange of strikes

Eugene Komchuk
2 hours ago

Justin Sun crypto exchange halts trading of Trump family stablecoin

Justin Sun crypto exchange halts trading of Trump family stablecoin

Olga Shendetskaya
05.06.2026

Strong May jobs report complicates Fed rate outlook

Strong May jobs report complicates Fed rate outlook

Hanna Syniavska
05.06.2026

Bitcoin falls below $62,000 after strong U.S. jobs report

Bitcoin falls below $62,000 after strong U.S. jobs report

Top 5 companies for you

United States

Live News

Dmytro Kharkov
Now

Bitcoin holds $60,000 support as crypto winter fears grow

Anton Kharitonov
Now

Apple remains under pressure ahead of WWDC 2026

Anton Kharitonov
Now

Bitcoin declines as investors reduce long positions

Anton Kharitonov
Now

WTI declines again amid demand concerns

Dmytro Kharkov
Now

SpaceX IPO could weigh on Tesla as investors chase new growth story

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.